These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26215435)

  • 1. Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.
    Mojtahedzadeh M; Lee ML; Friedman TC
    J Diabetes Complications; 2015; 29(8):1248-52. PubMed ID: 26215435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
    Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
    Aljabri K; Kozak SE; Thompson DM
    Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
    Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain in type 2 diabetes mellitus.
    Jacob AN; Salinas K; Adams-Huet B; Raskin P
    Diabetes Obes Metab; 2007 May; 9(3):386-93. PubMed ID: 17391167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Low (7.5 mg/day), Standard (15 mg/ day) and High (30 mg/day) Dose Pioglitazone Therapy on Glycemic Control and Weight Gain in Recently-Diagnosed Type 2 Diabetes Patients.
    Panikar V; Kale NJ; Hoskote SS; Deogaonkar N; Joshi SR
    J Assoc Physicians India; 2015 Nov; 63(11):36-9. PubMed ID: 29900709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
    Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
    Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
    Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
    Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.